文献速递胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗放疗物理与技术

VA放射肿瘤学质量监测项目

VA-Radiation Oncology Quality Surveillance Program.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-01-23

美国退伍军人健康管理局建立VA放射肿瘤学质量监测项目,采用临床质量测量指标评估40个VA放疗机构的诊疗质量。该项目由ASTRO专家小组定义前列腺癌、非小细胞肺癌和小细胞肺癌的质量指标及评分标准,从1567例患者电子病历中提取数据,总体质量指标通过率为82.4%,肺癌和前列腺癌分别为78.0%和87.2%,不同瘤种、临床路径和中心间存在明显差异。

要点

  • VA放疗质量监测项目基于临床质量指标,覆盖前列腺癌、非小细胞肺癌和小细胞肺癌。
  • 1567例评估病例总体质量指标通过率为82.4%,肺癌78.0%,前列腺癌87.2%。
  • 不同瘤种、临床路径和执行中心间质量指标通过率存在明显差异。

核心结论

  • 基于临床质量指标的VA放射肿瘤学监测项目允许提供者与同行比较临床实践并无干扰地调整个人诊疗模式。

研究设计与样本

  • 退伍军人健康管理局建立VA放射肿瘤学质量监测项目,采用美国放射学院放射肿瘤质量研究项目方法学开发临床质量指标。
  • ASTRO组织疾病部位专家小组为前列腺癌(中危和高危)、非小细胞肺癌(IIIA/B期)和小细胞肺癌(局限期)定义质量指标和评分标准。
  • 从40个VA放射肿瘤机构的电子病历和治疗管理及计划系统中提取1567例患者的数据元素。

主要发现

  • 1567例评估病例总体通过82.4%的所有质量指标。
  • 773例肺癌病例的质量指标通过率为78.0%,794例前列腺癌病例为87.2%。
  • 按肿瘤部位、临床路径或执行中心分别检查时,质量指标通过率存在明显差异。

关键数值与推荐

  • 前列腺癌(中危和高危)、非小细胞肺癌(IIIA/B期)和小细胞肺癌(局限期)的质量指标由ASTRO专家小组定义并建立评分标准。
  • 1567例评估病例总体质量指标通过率为82.4%,肺癌为78.0%,前列腺癌为87.2%。

临床怎么用

  • 提供者可通过同行评审保护的项目比较自身临床实践与同行,并无干扰地调整个人诊疗模式。
  • 质量指标数据反馈给医生,用于识别诊疗过程改进领域和循证建议的采纳情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to develop a quality surveillance program for approximately 15,000 US veterans treated at the 40 radiation oncology facilities at the Veterans Affairs (VA) hospitals each year. METHODS AND MATERIALS: State-of-the-art technologies were used with the goal to improve clinical outcomes while providing the best possible care to veterans. To measure quality of care and service rendered to veterans, the Veterans Health Administration established the VA Radiation Oncology Quality Surveillance program. The program carries forward the American College of Radiology Quality Research in Radiation Oncology project methodology of assessing the wide variation in practice pattern and quality of care in radiation therapy by developing clinical quality measures (QM) used as quality indices. These QM data provide feedback to physicians by identifying areas for improvement in the process of care and identifying the adoption of evidence-based recommendations for radiation therapy. RESULTS: Disease-site expert panels organized by the American Society for Radiation Oncology (ASTRO) defined quality measures and established scoring criteria for prostate cancer (intermediate and high risk), non-small cell lung cancer (IIIA/B stage), and small cell lung cancer (limited stage) case presentations. Data elements for 1567 patients from the 40 VA radiation oncology practices were abstracted from the electronic medical records and treatment management and planning systems. Overall, the 1567 assessed cases passed 82.4% of all QM. Pass rates for QM for the 773 lung and 794 prostate cases were 78.0% and 87.2%, respectively. Marked variations, however, were noted in the pass rates for QM when tumor site, clinical pathway, or performing centers were separately examined. CONCLUSIONS: The peer-review protected VA-Radiation Oncology Surveillance program based on clinical quality measures allows providers to compare their clinical practice to peers and to make meaningful adjustments in their personal patterns of care unobtrusively.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hagan M, Kapoor R, Michalski J, et al. VA-Radiation Oncology Quality Surveillance Program. Int J Radiat Oncol Biol Phys. 2020. PMID: 31983560. doi:10.1016/j.ijrobp.2019.08.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。